Contact information
German CLL Study Group
Department I of Internal Medicine
University Hospital of Cologne
Kerpener Straße 62
50937 Cologne
CV
Academic education
| 1990 - 1997 | Study of medicine with medical degree at the Medical Faculty of the Ludwig-Maximilians-University, Munich |
Scientific degrees
| 07/2019 | Adjunct Professor at the University Hospital of Cologne |
| 12/2011 | Habilitation and granted venia legend for the subject Internal Medicine, Medical Faculty of the University of Cologne |
| 1998 | MD thesis, Medical Faculty of the Ludwig-Maximilians-University, Munich Advisor: Prof. Dr. M. Hallek (Grade: Magna cum laude) |
| 06/2003 | Graduation from Medical School, University of Munich (Grade: Magna cum laude) |
Scientific career
| 2022 - present | Deputy Chair of the GCLLSG |
| 2020 - present | Advisory Board of the KML |
| 2020 - present | Program committee of the Society of Hematologic Oncology (SOHO) |
| 2018 - present | Advisory Board of the DGHO |
| 2018 - 2020 | Lancet Oncology International Advisory Board |
| 2016 - 2019 | Member of the Scientific program committee of EHA |
| 2016 - present | Member of the Scientific program committee of DGHO |
| 2015 - present | Member of the committee for promotion of young researchers by DGIM |
| 2012 - present | Consultant at the Department I for Internal Medicine, University of Cologne |
| 2006 - 2010 | Head of clinical trial unit at the Department I for Internal Medicine, University of Cologne |
| 2006 | Recognition of specialisation for Hematology and Medical Oncology by the medical Council Nordrhein |
| 2005 | Recognition of specialisation for Internal Medicine by the medical Council Bavaria |
| 2005 - present | Scientific associate at the Department I for Internal Medicine, University of Cologne |
| 2005 - 2022 | Secretary of the German CLL Study Group (GCLLSG) |
| 1998 - 2005 | Scientific associate at the Department III for Internal Medicine, Klinikum Großhadern of the Ludwig-Maximilians-University Munich |
| 1997 - 1998 | Intern at the Medical Clinic Innenstadt, Ludwig-Maximilians-University Munich |
Honors/ Awards/ Memberships
| 2018 | Fritz-Acker foundation, award for contribution in haematology and oncology |
| 2012 | Best habilitation in 2011 by the University of Cologne |
| German society for Hematology and Oncology (DGHO) | |
| German society for Internal Medicine (DGIM) | |
| Competent net malignant lymphoma (KML) | |
| European Hematology Association (EHA) | |
| American Society of Hematology (ASH) |
Publications
-
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of an aggressive lymphoma that is associated with poor response to chemotherapy and short survival. We initiated an international, investigator-initiated, prospective, open-label phase 2 study in…
-
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
BACKGROUND Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. METHODS In a phase 3, open-label trial, we randomly assigned,…
-
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized…
-
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Background: In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
-
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
-
Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
-
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the…
-
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
Fludarabine, cyclophosphamide and rituximab (FCR) was compared to bendamustine and rituximab (BR) in an international, randomized, open label, phase 3 trial in 561 previously untreated, fit patients with chronic lymphocytic leukemia (CLL) without del (17p). Primary endpoint was progression free…
-
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
-
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell lymphoma, we asked if epigenetic events might be involved in venetoclax…